Spotlight on capecitabine for the treatment of unresectable or metastatic carcinoma of various origin: A retrospective study of 25 dogs.
antimetabolite
canine
carcinoma
clinical benefit
oral chemotherapy
toxicity
Journal
Veterinary and comparative oncology
ISSN: 1476-5829
Titre abrégé: Vet Comp Oncol
Pays: England
ID NLM: 101185242
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
revised:
31
10
2023
received:
24
03
2023
accepted:
20
11
2023
medline:
1
12
2023
pubmed:
1
12
2023
entrez:
1
12
2023
Statut:
aheadofprint
Résumé
Capecitabine, the oral prodrug of 5-fluorouracil, is indicated in people to treat various malignant epithelial cancers. In dogs, capecitabine has not been extensively evaluated. The aim of this retrospective study was to investigate toxicity and preliminary efficacy of single agent capecitabine in dogs with advanced malignant epithelial cancers of any site, for which no effective therapy existed, conventional treatment failed or was declined. Capecitabine was administered orally at 750 mg/m
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd.
Références
Budman DR, Meropol NJ, Reigner B, et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol. 1998;16(5):1795-1802. doi:10.1200/JCO.1998.16.5.1795
Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34(8):1274-1281. doi:10.1016/s0959-8049(98)00058-6
Bashey A, Sundaram S, Corringham S, et al. Use of capecitabine as first-line therapy in patients with metastatic breast cancer relapsing after high-dose chemotherapy and autologous stem cell support. Clin Oncol (R Coll Radiol). 2001;13(6):434-437. doi:10.1053/clon.2001.9307
Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19(8):2282-2292. doi:10.1200/JCO.2001.19.8.2282
Jakob A, Bokemeyer C, Knop S, Schupp M, Mayer F, Kanz L. Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation-a phase II study. Anticancer Drugs. 2002;13(4):405-410. doi:10.1097/00001813-200204000-00009
Bedard PL, Bernard-Marty C, Raimoni C, Cardoso F. The role of capecitabine in the management of breast cancer in elderly patients. J Geriatr Oncol. 2011;2:72-81.
Saif MW, Katirtzoglou NA, Syrigos KN. Capecitabine: an overview of the side effects and their management. Anticancer Drugs. 2008;19(5):447-464. doi:10.1097/CAD.0b013e3282f945aa
Leicher LW, de Graaf JC, Coers W, Tascilar M, de Groot JW. Tolerability of capecitabine monotherapy in metastatic colorectal cancer: a real-world study. Drugs R D. 2017;17(1):117-124. doi:10.1007/s40268-016-0154-8
Hennessy BT, Gauthier AM, Michaud LB, Hortobagyi G, Valero V. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson cancer center and a review of capecitabine toxicity in the literature. Ann Oncol. 2005;16(8):1289-1296. doi:10.1093/annonc/mdi253
Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet. 2001;40(2):85-104. doi:10.2165/00003088-200140020-00002
Schmiedt C, Penzo C, Schwab M, Dubielzig R, McAnulty J. Use of capecitabine after renal allograft transplantation in dog erythrocyte antigen-matched dogs. Vet Surg. 2006;35(2):113-124. doi:10.1111/j.1532-950X.2006.00122.x
Milovancev M, Schmiedt CW, Bentley E, et al. Use of capecitabine to prevent acute renal allograft rejection in dog erythrocyte antigen-mismatched mongrel dogs. Vet Surg. 2007;36(1):10-20. doi:10.1111/j.1532-950X.2007.00230.x
Zarfoss M, Bentley E, Milovancev M, Schmiedt C, Dubielzig R, McAnulty J. Histopathologic evidence of capecitabine corneal toxicity in dogs. Vet Pathol. 2007;44(5):700-702. doi:10.1354/vp.44-5-700
Chang SC, Liao JW. Mesojejunoileac liposarcoma with intrahepatic metastasis in a dog. J Vet Med Sci. 2008;70(6):637-640. doi:10.1292/jvms.70.637
Meier V, Polton G, Cancedda S, et al. Outcome in dogs with advanced (Stage 3b) anal sac gland carcinoma treated with surgery or hypofractionated radiation therapy. Vet Comp Oncol. 2017;15(3):1073-1086. doi:10.1111/vco.12248
Smith AA, Frimberger AE, Moore AS. Retrospective study of survival time and prognostic factors for dogs with small intestinal adenocarcinoma treated by tumor excision with or without adjuvant chemotherapy. J Am Vet Med Assoc. 2019;254(2):243-250. doi:10.2460/javma.254.2.243
Merino-Gutierrez V, Borrego JF, Puig J, Hernández A, Clemente-Vicario F. Treatment of advanced-stage canine nasal carcinomas with toceranib phosphate: 23 cases (2015-2020). J Small Anim Pract. 2021;62(10):881-885. doi:10.1111/jsap.13387
Alonso-Miguel D, Valdivia G, García-San José P, et al. Clinical outcome of dogs diagnosed with canine inflammatory mammary cancer treated with metronomic cyclophosphamide, a cyclooxygenase-2 inhibitor and toceranib phosphate. Vet Comp Oncol. 2022;20(1):179-188. doi:10.1111/vco.12760
Veterinary Cooperative Oncology Group. Common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol. 2016;14(4):417-446. doi:10.1111/vco.283
Nguyen SM, Thamm DH, Vail DM, London CA. Response evaluation criteria for solid tumours in dogs (v1.0): a veterinary cooperative oncology group (VCOG) consensus document. Vet Comp Oncologia. 2015;13(3):176-183. doi:10.1111/vco.12032
London C, Mathie T, Stingle N, et al. Preliminary evidence for biologic activity of toceranib phosphate (palladia(®)) in solid tumours. Vet Comp Oncol. 2012;10(3):194-205. doi:10.1111/j.1476-5829.2011.00275.x
Marconato L, Finotello R. Veterinary oncologists adapting to COVID-19 pandemic. Vet Comp Oncol. 2020;18(3):257. doi:10.1111/vco.12593
Van Cutsem E, Hoff PM, Harper P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer. 2004;90(6):1190-1197. doi:10.1038/sj.bjc.6601676
Church EM, Mehlhaff CJ, Patnaik AK. Colorectal adenocarcinoma in dogs: 78 cases (1973-1984). J Am Vet Med Assoc. 1987;191(6):727-730.
Pelizzaro F, Sammarco A, Dadduzio V, et al. Capecitabine in advanced hepatocellular carcinoma: A multicenter experience. Dig Liver Dis. 2019;51(12):1713-1719. doi:10.1016/j.dld.2019.06.015
Brandi G, Venturi M, De Lorenzo S, et al. Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases. Cancer Commun (Lond). 2018;38(1):41. doi:10.1186/s40880-018-0312-1
Liptak JM, Dernell WS, Monnet E, et al. Massive hepatocellular carcinoma in dogs: 48 cases (1992-2002). J Am Vet Med Assoc. 2004;225(8):1225-1230. doi:10.2460/javma.2004.225.1225